ArticleFrontiers in neurology
Hemoglobin-albumin-lymphocyte-platelet score and early neurological deterioration in acute ischemic stroke: a single-center retrospective cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the association between the hemoglobin-albumin-lymphocyte-platelet (HALP) score and early neurological deterioration (END) in individuals with stroke and to develop an exploratory prediction model for END. Patients and methods: Clinical data from 595 patients with acute ischemic stroke (AIS) admitted to the Affiliated Hospital of Xuzhou Medical University from April 2022 to April 2024 were retrospectively analyzed. Patients were randomly divided into a training set and a validation set in a 7:3 ratio. Multivariable logistic regression analysis was utilized in the training data to examine END risk variables and build a corresponding predictive model. Model performance was evaluated using receiver operating characteristic (ROC) curves to assess discrimination and the Hosmer-Lemeshow goodness-of-fit test to evaluate calibration. Clinical decision curve analysis (DCA) was further applied to determine the model's clinical value. To improve interpretability, the importance of included predictors was assessed using the SHapley Additive exPlanation (SHAP) method. Results: Of the 595 patients, 186 (31.3%) developed early neurological deterioration (END), while the remaining 409 (68.7%) comprised the non-END group. The training cohort consisted of 416 randomly assigned participants. Multivariate logistic regression showed that the large artery atherosclerosis (LAA) subtype, elevated baseline National Institutes of Health Stroke Scale (NIHSS) score, and lower HALP score constituted independent determinants for END development ( Conclusion: A lower HALP score was associated with END in patients with AIS. A nomogram incorporating HALP score, LAA subtype, and baseline NIHSS score demonstrated moderate discrimination and may provide useful information for early risk stratification in AIS. This prediction model requires validation in a larger, prospective clinical study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.